• By: Yuka Osada
• On: April 23, 2026

U.S. FDA Tightens Oversight of Cross-border Cell Exports!

• By: Yuka Osada
• On: March 19, 2026

US FDA CMC Strategy: CGT Comparability and BLA Readiness

• By: Yuka Osada
• On: February 19, 2026

FY 2026: FDA Device Registration, Listing & User Fees

• By: Yuka Osada
• On: February 12, 2026

PreCheck Program: FDA’s Roadmap for US Drug Manufacturing

• By: Yuka Osada
• On: January 22, 2026

Eye on the Horizon: The $79B Evolution of Ophthalmic Therapies

• By: Yuka Osada
• On: January 15, 2026

Navigating the 2026 “CMC Cliff” for AAV Gene Therapy

• By: Yuka Osada
• On: October 1, 2025

U.S. vs. Foreign Sponsors: Who Really Manages Drug Shortages?

• By: Yuka Osada
• On: September 17, 2025

Registration & Listing of Cosmetic Facilities and Products in the US

• By: Yuka Osada
• On: August 20, 2025

FDA Expands Surprise Inspections at Overseas Manufacturing Sites